(Q37520586)

20 August 2017

1 reference

title

Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy (English)

1 reference

20 August 2017

E Jason Abel

1

1 reference

20 August 2017

Christopher G Wood

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

16 June 2009

1 reference

20 August 2017

published in

Nature Reviews Urology

1 reference

20 August 2017

volume

6

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

375-383

1 reference

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Prognostic models and algorithms in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Renal cell carcinoma: current status and emerging therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Identification of the von Hippel-Lindau disease tumor suppressor gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Role of VHL gene mutation in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Surgery for Metastatic Renal Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Spontaneous regression of metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

VEGF-targeted therapy in metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive nephrectomy in metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Using protein expressions to predict survival in clear cell renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive Partial Nephrectomy Does Not Undermine Cancer Control in Metastatic Renal Cell Carcinoma: A Population-Based Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Presurgical therapy in metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Adjuvant and neoadjuvant therapy in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Outcome and survival with nonsurgical management of renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Pre-surgical targeted molecular therapy in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Nephrectomy for metastatic renal cell carcinoma: Indiana University experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2009.102

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

31 March 2020

1 reference

12 December 2020

Cytotoxic chemotherapy for advanced renal cell carcinoma.

1 reference

12 December 2020

The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy

1 reference

12 December 2020

NCCN clinical practice guidelines in oncology: kidney cancer

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor

1 reference

12 December 2020

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

12 December 2020

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

1 reference

12 December 2020

Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma

1 reference

12 December 2020

Cytoreductive surgery for stage IV renal cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2009.102

1 reference

Dimensions Publication ID

20 August 2017

1050033113

0 references

1 reference